| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.32 | 4e-11 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | 0.23 | 1e-09 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-06 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.14 | 8e-06 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.21 | 3e-05 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.15 | 0.001 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.15 | 0.001 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |